Device Trial Radar · NCT03741205
Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patients With a Recent Non-diagnostic EMU Visit
Last checked: Nov 20, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 1, 2020
Primary completion
Jan 2021
Study completion Jan 2026
Sponsor
- Lead sponsor
- Brain SentinelAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 14, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, randomized, prospective study of the impact on healthcare utilization of a surface Electromyography (sEMG) based seizure monitoring and alerting system for Veterans with seizures with upper extremity motor involvement, who have had a recent non-diagnostic EMU stay.
Conditions
- Epilepsy
Interventions
SPEAC SystemDevice
Surface Electromyography (sEMG) based seizure monitoring and alerting system
Primary outcomes
What the sponsor says the trial is designed to measure.
- Diagnostic Impact Form QuestionnaireTime frame: up to 5 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.